US stock · Healthcare sector · Medical Instruments & Supplies
Company Logo

AngioDynamics, Inc.

ANGONASDAQ

12.25

USD
-0.07
(-0.57%)
Market Closed
-13.44P/E
111Forward P/E
-0.64P/E to S&P500
489.900MMarket CAP
- -Div Yield
Upcoming Earnings
30 Mar
Shares Short
2/28/23
1.16M
Short % of Float
3.73%
Short % of Shares Outs.
2.95%
% Held by Insiders
5.03%
% Held by Institutions
96.21%
Beta
0.62
PEG Ratio
-83.93
52w. high/low
24.87/11.33
Avg. Daily Volume
0.37M
Return %
Stock
S&P 500
1 year
(49.02)
(9.05)
3 years
32.24
50.26
5 years
(31.68)
38.50
Scale: |
High
Low
20.76
9.12
16.30
9.72
17.86
13.61
17.73
12.60
15.12
10.00
17.37
9.52
19.30
13.06
19.80
11.14
17.64
9.71
18.85
14.80
24.49
15.16
25.48
13.72
17.24
7.48
32.00
14.96
30.00
11.71
15.96
11.33
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
6.08
6.91
8.01
8.79
8.68
8.74
9.82
10.09
10.00
9.79
9.55
9.29
7.22
6.96
7.59
8.11
8.35
Earnings per share
(0.49)
0.45
0.41
0.50
0.33
(0.20)
(0.02)
0.09
(0.09)
(1.21)
0.14
0.44
(0.30)
(4.39)
(0.82)
(0.68)
(0.83)
FCF per share
0.08
0.80
(0.06)
1.20
1.24
0.35
0.40
0.34
0.36
1.10
1.44
1.01
0.92
(0.58)
0.49
(0.29)
(0.57)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.40
0.28
0.88
0.43
0.12
0.10
0.37
0.38
0.37
0.15
0.08
0.10
0.08
0.20
0.14
0.11
0.12
Book Value per sh.
18.22
14.77
15.28
15.92
16.31
20.63
15.13
15.31
15.27
14.03
14.07
14.64
16.40
11.98
11.46
10.88
10.67
Comm.Shares outs.
18
24
24
25
25
25
35
35
36
36
37
37
37
38
38
39
39
Avg. annual P/E ratio
(39.6)
32.9
32.5
30.7
46.1
(59.3)
(707.1)
177.5
(171.1)
(11.6)
121.4
44.9
(64.9)
(2.6)
(30.0)
(29.5)
(13.4)
P/E to S&P500
(2.3)
1.5
0.5
1.5
2.8
(4.0)
(41.5)
9.8
(8.5)
(0.5)
5.1
1.8
(2.7)
(0.1)
(1.0)
(1.4)
(0.6)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
112
167
195
216
216
222
342
354
357
354
350
344
271
264
291
316
328
Operating margin
(10.0)%
9.8%
8.3%
9.7%
5.5%
(1.3)%
2.1%
3.8%
(0.3)%
0.3%
3.7%
3.1%
(3.5)%
(63.3)%
(12.1)%
(9.0)%
(10.1)%
Depreciation (m)
3
9
12
13
13
13
29
25
30
28
25
23
26
24
26
29
31
Net profit (m)
(9)
11
10
12
8
(5)
(1)
3
(3)
(44)
5
16
(11)
(167)
(32)
(27)
(33)
Income tax rate
(27.3)%
37.2%
34.5%
37.2%
24.1%
3.6%
4.8%
51.6%
59.1%
(1,240.0)%
49.1%
(118.8)%
24.2%
0.8%
12.5%
11.4%
8.3%
Net profit margin
(8.1)%
6.5%
5.1%
5.7%
3.8%
(2.3)%
(0.2)%
0.9%
(0.9)%
(12.3)%
1.4%
4.7%
(4.1)%
(63.1)%
(10.8)%
(8.4)%
(9.9)%
Working capital (m)
107
101
119
145
169
104
78
80
95
80
82
111
242
101
83
69
85
Long-term debt (m)
17
7
7
7
6
143
135
138
129
105
91
87
124
40
20
25
50
Equity (m)
336
356
372
391
406
524
527
538
545
507
515
543
615
455
439
424
408
ROIC
(2.5)%
3.0%
2.7%
3.2%
2.1%
(0.7)%
0.6%
0.7%
(0.3)%
0.3%
1.0%
3.6%
(1.0)%
(30.6)%
(6.1)%
(5.4)%
(6.4)%
Return on capital
(1.9)%
4.2%
3.9%
4.8%
2.6%
(0.7)%
0.6%
1.3%
(0.6)%
0.0%
1.8%
1.5%
(1.1)%
(28.1)%
(6.3)%
(5.3)%
(6.1)%
Return on equity
(2.7)%
3.1%
2.7%
3.1%
2.0%
(1.0)%
(0.1)%
0.6%
(0.6)%
(8.6)%
1.0%
3.0%
(1.8)%
(36.7)%
(7.2)%
(6.3)%
(8.0)%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
(22.1)%
- -
- -
- -
23.4%
- -
- -
- -
- -
25.7%
- -
- -
- -
- -
- -
- -
Capital Structure
6 Jan · 2023 | Q2
All numbers in millions
Total liabilities
$ 150
Total assets
$ 558
Long-term debt
$ 50
Cash and equiv.
$ 30
Goodwill
$ 201
Retained earnings
$ (180)
Common stock
39
Enterprise Value
$ 510
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
54
48
29
Receivables
34
37
56
Inventory
60
49
51
Other
4
1
(19)
Current assets
153
141
143
Acc. Payable
19
20
28
Debt due
1
- -
9
Other
32
38
37
Current liabilities
51
58
74
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
8.66%
(1.24)%
(0.47)%
Cash flow
(160.78)%
(129.87)%
(35.03)%
Earnings
(15.85)%
282.80%
185.48%
Dividends
- -
- -
- -
Book value
(3.41)%
(4.87)%
(1.79)%
Insider Trading
Type
Shares
Date
Trowbridge Stephen A
InKind
555
02/03/23
Rosenzweig Richard C
InKind
1,137
02/01/23
Helsel Dave
Sale
4,633
01/31/23
Trowbridge Stephen A
Purchase
1,083
10/12/22
Clemmer James C
Purchase
10,000
10/10/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
70
73
71
77
291
2022
77
78
74
87
316
2023
82
85
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
(0.11)
(0.11)
(0.09)
(0.51)
(0.82)
2022
(0.18)
(0.21)
(0.13)
(0.16)
(0.68)
2023
(0.33)
(0.21)
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Instruments & Supplies
CEO:
Mr. James C. Clemmer
Full-time employees:
760
City:
Latham
Address:
14 Plaza Drive
IPO:
May 27, 2004
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.